Cefepime

Chemical formula: C₁₉H₂₄N₆O₅S₂  Molecular mass: 480.561 g/mol  PubChem compound: 5479537

Therapeutic indications

Cefepime is indicated for:

Lower respiratory tract infections

Population group: only adolescents (12 years - 18 years old) , adults (18 years old or older)

Cefepime is indicated in the treatment of infections caused by bacteria that are cefepime-sensitive: lower respiratory tract infections, including nosocomial pneumonia and community acquired pneumonia, acute bacterial exacerbation of chronic bronchitis and secondary bacterial infection of acute bronchitis.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Uncomplicated and complicated urinary tract infections

Population group: only adolescents (12 years - 18 years old) , adults (18 years old or older)

Cefepime is indicated in the treatment of infections caused by bacteria that are cefepime-sensitive: uncomplicated and complicated urinary tract infections, including pyelonephritis.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Infection of skin and/or subcutaneous tissue

Population group: only adolescents (12 years - 18 years old) , adults (18 years old or older)

Cefepime is indicated in the treatment of infections caused by bacteria that are cefepime-sensitive: skin and subcutaneous infections.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Intra-abdominal infections, peritonitis, biliary tract infections

Population group: only adolescents (12 years - 18 years old) , adults (18 years old or older)

Cefepime is indicated in the treatment of infections caused by bacteria that are cefepime-sensitive: intra-abdominal infections, including peritonitis and biliary tract infections.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Gynaecological infections

Population group: only adolescents (12 years - 18 years old) , adults (18 years old or older)

Female genital infection and additionally Cefepime susceptible species

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Bacterial meningitis

Population group: only infants (40 days - 1 year old) , children (1 year - 12 years old)

Bacterial meningitis and additionally Cefepime susceptible species

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Bacterial infection with neutropenic fever

Population group: only adolescents (12 years - 18 years old) , adults (18 years old or older)

In combination with other antibacterial agents in the management of neutropenic patients with fever that is suspected to be due to a bacterial infection.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Bacterial infection with neutropenic fever

Population group: only infants (40 days - 1 year old) , children (1 year - 12 years old)

Bacterial infectious disease and additionally Febrile neutropenia and additionally Cefepime susceptible species

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Lower respiratory tract infections

Population group: only infants (40 days - 1 year old) , children (1 year - 12 years old)

Cefepime is indicated in the treatment of infections caused by bacteria that are cefepime-sensitive: lower respiratory tract infections, including nosocomial pneumonia and community acquired pneumonia, acute bacterial exacerbation of chronic bronchitis and secondary bacterial infection of acute bronchitis.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Uncomplicated and complicated urinary tract infections

Population group: only infants (40 days - 1 year old) , children (1 year - 12 years old)

Cefepime is indicated in the treatment of infections caused by bacteria that are cefepime-sensitive: uncomplicated and complicated urinary tract infections, including pyelonephritis.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Infection of skin and/or subcutaneous tissue

Population group: only infants (40 days - 1 year old) , children (1 year - 12 years old)

Cefepime is indicated in the treatment of infections caused by bacteria that are cefepime-sensitive: skin and subcutaneous infections.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Intra-abdominal infections, peritonitis, biliary tract infections

Population group: only infants (40 days - 1 year old) , children (1 year - 12 years old)

Cefepime is indicated in the treatment of infections caused by bacteria that are cefepime-sensitive: intra-abdominal infections, including peritonitis and biliary tract infections.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Contraindications

Cefepime is contraindicated in the following cases:

Hypersensitivity to cephalosporins, history of hypersensitivity reaction to penicillins, monobactams or carbapenems

at least one of
Cephalosporin allergy
Allergy to penicillin
Monobactam allergy
Carbapenem allergy

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines

Summary of Product Characteristics (SPC) 2017: RENAPIME Powder for solution for injection / infusion
< Previous: Overview
Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈